GT
KURA icon

Glenmede Trust’s Kura Oncology KURA Stock Holding History

Glenmede Trust’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,298
Closed -$304K – 1515
2025
Q4 		$304K Buy
+29,298
New +$307K ﹤0.01% 1135
2025
Q1 		– Sell
-19,076
Closed -$166K – 1410
2024
Q4 		$166K Buy
19,076
+5,499
+41% +$79.1K ﹤0.01% 1257
2024
Q3 		$265K Buy
13,577
+92
+0.7% +$1.86K ﹤0.01% 1144
2024
Q2 		$278K Buy
13,485
+730
+6% +$15K ﹤0.01% 1081
2024
Q1 		$272K Buy
+12,755
New +$248K ﹤0.01% 1082

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenmede Trust's KURA Position: Q1 2026 in Review

Glenmede Trust sold out of Kura Oncology (KURA) in Q1 2026, closing a stake of 29,298 shares — an estimated $304K sold.

Glenmede Trust first reported a position in KURA in Q1 2024 and held it in 5 quarters. The position peaked at $304K in Q4 2025. 222 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • Glenmede Trust reported no remaining Kura Oncology position as of Q1 2026 after selling out during the quarter.
  • Glenmede Trust sold 29,298 Kura Oncology shares in Q1 2026, an estimated $304K.
  • Glenmede Trust first reported a position in Kura Oncology in Q1 2024 and held it in 5 quarters.
  • Glenmede Trust's Kura Oncology position peaked at $304K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.